Find clinical trials for Lymphoma in Columbus, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Columbus, OH, USA:

Status recently updated

Epcoritamab and Rituximab for First-line Follicular Lymphoma

of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma...

Enrolling

Active, not recruiting

Low Grade Non-Hodgkin's Lymphoma, Adult

Follicular Lymphoma

Drug: Rituximab

Drug: Epcoritamab

Phase 2

Reid Merryman, MD

Columbus, Ohio, United States and 3 other locations

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...

Active, not recruiting

Lymphoma, Malignant

Non-hodgkin Lymphoma

Drug: DS-3201b

Phase 1

Daiichi Sankyo

Columbus, Ohio, United States and 20 other locations

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting

B Cell Lymphoma

Mantle Cell Lymphoma

Drug: Ibrutinib

Drug: Palbociclib

Phase 2

Alliance Foundation Trials

Columbus, Ohio, United States and 8 other locations

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting

Non-Hodgkin Lymphoma

Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis

Columbus, Ohio, United States and 66 other locations

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting

Non Hodgkin Lymphoma

Drug: acalabrutinib

Drug: rituximab (IV)

Phase 1, Phase 2